NSF-DBA Expands Pharmaceutical Services in India through Collaborative Agreement with Semler Research Center

NSF-DBA, an NSF International Health Sciences Company with more than 25 years of experience in the pharmaceutical industry, has signed a collaborative agreement with Semler Research Center Pvt Ltd.

(SRC) of Bangalore to expand pharmaceutical training, auditing, consulting and testing services throughout India.

India has one of the fastest growing pharmaceutical markets in the world. Currently ranked 14th, India's pharma market is expected to grow by $14 billion, becoming the 10th largest pharma market by 20151. NSF-DBA's partnership with SRC provides global and India-based pharmaceutical companies with local access to essential training, consulting, auditing and testing services. More than 150 companies worldwide ranging from top 10 pharmaceutical companies to small start-ups rely on NSF-DBA's services to help ensure the safety and quality of their suppliers and pharmaceutical products.

SRC, the Indian subsidiary of a U.S.-based Arnold A Semler Inc., specializes in all aspects of pharmaceutical development, clinical services, bioavailability/bioequivalence testing and GxP2 auditing and consulting. Under the collaborative agreement, NSF-DBA will work with SRC to harmonize consulting and auditing practices and standards, as well as train SRC staff to deliver NSF-DBA training courses. In addition, NSF-DBA services in India now include:

• GxP Consultancy Services
Through SRC's team of GxP expert consultants in India, NSF-DBA can provide auditing, consulting, onsite GMP remediation and validation, and training to international standards for pharmaceuticals, medical devices, and dietary supplements.

• Clinical Services
NSF-DBA can now provide phase I clinical studies and bioavailability/bioequivalence studies, including the design and management of clinical trials from Phase I to Phase IV for pharmaceutical enterprises.

• Bioanalytical Services
NSF-DBA can now provide extensive laboratory capabilities in India, including analysis of samples in support of bioavailability/bioequivalence studies.

• Formulation, Process and Analytical Development
SRC's Bangalore facility maintains pilot scale manufacturing equipment, allowing NSF-DBA to develop formulations and processes for a range of dosage forms - from oral solids, through semi-solids, to liquid injectables.

“We asked for recommendations from trusted clients and professionals in the region and one name came up time after time - SRC in Bangalore,” said Bob Pietrowski, NSF-DBA Managing Partner. “This agreement with SRC allows NSF-DBA to better assist companies in Europe and North America who are seeking audits of suppliers and contractors in the region as part of their supply chain assurance program.”

“This collaboration with NSF-DBA brings a host of high quality and competitively priced pharmaceutical services to companies based in India. The consultants of SRC, trained by the reputed Senior Consultants of NSF-DBA, provide a wide range of services, including auditing of API (active pharmaceutical ingredient) facilities, training, consulting, pre-audit services, due diligence audit, and other pharmaceutical-related services that help ensure the safety of pharmaceuticals,” said Gurudatta G.G., Chief Quality Officer, SRC.

For additional information on NSF-DBA's services worldwide, visit the NSF-DBA website or contact Bob Pietrowski, NSF-DBA Managing Partner, at +44 (0) 1751 432 999.

Editor's note: To schedule an interview with an expert from NSF-DBA, contact Greta Houlahan at +1 734-913-5723.
Companies in this article
More in Home